Closing the Gaps in NSCLC

Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deaconess Medical Center, shares strategies to help patients understand these processes and set realistic expectations.

Guest: Deepa Rangachari, MD Communication is the key to guiding patients with non-small cell lung cancer through testing and treatment, but what exactly does that look like? Dr. Deepa Rangachari, an oncologist at the Beth Israel Deaconess Medical Center, shares strategies to help patients understand these processes and set realistic expectations.

Guest: Deepa Rangachari, MD With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could change our approach to treating patients with non-small cell lung cancer.

Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaconess Medical Center, expresses the importance of finding therapeutic strategies to help patients manage symptoms.

Host: Jennifer Caudle, DO Guest: Deepa Rangachari, MD Survival rates for patients with non-small cell lung cancer have notably improved thanks to the development of targeted therapies and immunotherapies. With these recent advancements on the forefront, Dr. Deepa Rangachari joins Dr. Jennifer Caudle to discuss the KEYNOTE-189 study and how it could change our approach to treating patients with non-small cell lung cancer.

Guest: Deepa Rangachari, MD Living with non-small cell lung cancer means living with a daily burden of symptoms like fatigue, decreased appetite, and shortness of breath. Dr. Deepa Rangachari, an oncologist at Harvard’s Beth Israel Deaconess Medical Center, expresses the importance of finding therapeutic strategies to help patients manage symptoms.

Guest: Joshua Bauml, MD The COVID-19 pandemic has presented a unique and difficult problem for clinicians and patients alike. Here to share how he’s continuing treatment for his patients with non-small cell lung cancer in the era of COVID-19 is Dr. Joshua Bauml, a medical oncologist and Assistant Professor at the Perelman School of Medicine at the University of Pennsylvania.

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges. To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Guest: Joshua Bauml, MD When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Guest: Joshua Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.

Guest: Joshua Bauml, MD When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncologist and Assistant Professor at the University of Pennsylvania’s Perelman School of Medicine.

Guest: Joshua Bauml, MD Tune in to hear medical oncologist Dr. Joshua Bauml from the University of Pennsylvania explain the difference between RET fusions and RET point mutations and how they each affect our treatment approach.

Guest: Joshua Bauml, MD The COVID-19 pandemic has presented a unique and difficult problem for clinicians and patients alike. Here to share how he’s continuing treatment for his patients with non-small cell lung cancer in the era of COVID-19 is Dr. Joshua Bauml, a medical oncologist and Assistant Professor at the Perelman School of Medicine at the University of Pennsylvania.

Host: Mario R. Nacinovich, Jr., MSc Guest: Lyudmila Bazhenova, MD Targeted therapies for oncogenic mutations in non-small cell lung cancer have shown a lot of potential when it comes to tailoring systemic treatment strategies to more specific tumor types and mutations. But just like any other therapeutic approach, it’s not without its challenges. To learn more about how we can identify these oncogenic drivers in our patients and what we should keep in mind when using targeted therapies, Mario Nacinovich sits down Dr. Lyudmila Bazhenova, board-certified medical oncologist and Professor of Medicine at the University of California San Diego.

Guest: Joshua Bauml, MD When a patient with non-small cell lung cancer harboring a molecular driver alteration develops resistance to their therapy, it’s important that we identify what the source of that resistance is, as Dr. Joshua Bauml from the University of Pennsylvania explains.

Guest: Joshua Bauml, MD Now that there are more targeted therapies available for metastatic non-small cell lung cancer, what are the best practices for evaluating our patients? Dr. Joshua Bauml elaborates on the opportunities and challenges faced when testing for oncogenic drivers in non-small cell lung cancer.

Guest: Joshua Bauml, MD When a patient presents with non-small cell lung cancer, one question that comes up is: Could this patient have a RET fusion? Here to explore how we can answer that question is Dr. Joshua Bauml, medical oncologist and Assistant Professor at the University of Pennsylvania’s Perelman School of Medicine.

Guest: Joshua Bauml, MD Tune in to hear medical oncologist Dr. Joshua Bauml from the University of Pennsylvania explain the difference between RET fusions and RET point mutations and how they each affect our treatment approach.

Guest: Fred R. Hirsch, MD, PhD Here to walk us through our current understanding of oncogene addiction and the resulting progress that’s been made in lung cancer treatment is Dr. Fred Hirsch from Mount Sinai.

Guest: Fred R. Hirsch, MD, PhD Here to walk us through our current understanding of oncogene addiction and the resulting progress that’s been made in lung cancer treatment is Dr. Fred Hirsch from Mount Sinai.

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory J Kubicek, MD What treatments and technologies are on the horizon for our patients with non-small cell lung cancer? Joining Mario Nacinovich to give us a look at what’s ahead is Dr. Gregory Kubicek, staff radiation oncologist at the MD Anderson Cooper Cancer Center.

Host: Mario R. Nacinovich, Jr., MSc Guest: Gregory J Kubicek, MD What treatments and technologies are on the horizon for our patients with non-small cell lung cancer? Joining Mario Nacinovich to give us a look at what’s ahead is Dr. Gregory Kubicek, staff radiation oncologist at the MD Anderson Cooper Cancer Center.

Guest: Jacob Sands, MD Take a deep dive into the data from a recent clinical trial exploring next generation sequencing in lung squamous cell carcinoma with Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.

Guest: Jacob Sands, MD Take a deep dive into the data from a recent clinical trial exploring next generation sequencing in lung squamous cell carcinoma with Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.

Guest: Jacob Sands, MD Although a lung cancer diagnosis can take a heavy toll on a patient’s mental and emotional well-being, there are counseling strategies you can use to better communicate with your patients and to ease their fears. Here to share the strategies he uses to help his patients cope with a lung cancer diagnosis is Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.

Guest: Jacob Sands, MD Armed with encouraging data from clinical trials, thoracic medical oncologist Dr. Jacob Sands walks us through the lung cancer screening technology that has the potential to save about 48,000 lives per year.

Guest: Jacob Sands, MD From an extensive database to a multidisciplinary team, thoracic medical oncologist Dr. Jacob Sands walks us through the essential components of a lung cancer screening program.

Guest: Jonathan Riess, MD, MS When treating patients with non-small cell lung cancer, their physical, mental, and emotional health need to be considered. That’s why Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center, is here to explain how he approaches caring for patients with non-small cell lung cancer.

Guest: Jonathan Riess, MD, MS After beginning treatment for non-small cell lung cancer, it’s important to think about how a patient's body reacts. Tune in as Associate Professor of Oncology and Hematology at the UC Davis Medical Center Dr. Jonathan Riess discusses his top-of-mind considerations for managing toxicities throughout the care course as well as which members of the multidisciplinary care team are important to managing this.

Guest: Jacob Sands, MD Although a lung cancer diagnosis can take a heavy toll on a patient’s mental and emotional well-being, there are counseling strategies you can use to better communicate with your patients and to ease their fears. Here to share the strategies he uses to help his patients cope with a lung cancer diagnosis is Dr. Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School.

Guest: Jacob Sands, MD Armed with encouraging data from clinical trials, thoracic medical oncologist Dr. Jacob Sands walks us through the lung cancer screening technology that has the potential to save about 48,000 lives per year.

Guest: Jacob Sands, MD From an extensive database to a multidisciplinary team, thoracic medical oncologist Dr. Jacob Sands walks us through the essential components of a lung cancer screening program.

Guest: Jonathan Riess, MD, MS When treating patients with non-small cell lung cancer, their physical, mental, and emotional health need to be considered. That’s why Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center, is here to explain how he approaches caring for patients with non-small cell lung cancer.

Guest: Jonathan Riess, MD, MS After beginning treatment for non-small cell lung cancer, it’s important to think about how a patient's body reacts. Tune in as Associate Professor of Oncology and Hematology at the UC Davis Medical Center Dr. Jonathan Riess discusses his top-of-mind considerations for managing toxicities throughout the care course as well as which members of the multidisciplinary care team are important to managing this.

Guest: Edward S. Kim, MD RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

Guest: Edward S. Kim, MD RET mutations or rearrangements have been observed in many cancers—including non-small cell lung cancer. But what does this genetic marker mean for our patients and the treatment landscape as a whole? That’s the question Dr. Edward Kim is here to answer.

Host: Jennifer Caudle, DO Guest: Michael R. Shafique, MD Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a real-world patient case from Dr. Michael Shafique’s experience as an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Guest: Michael R. Shafique, MD Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.

Guest: Michael R. Shafique, MD To find out more about the structure, results, and implications of the REVEL trial, we spoke with Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Host: Jennifer Caudle, DO Guest: Michael R. Shafique, MD Although only a small percentage of patients with non-small cell lung cancer have a genetic mutation involving the RET gene, it’s still essential that we know how this specific mutation impacts our diagnostic and treatment approach. That’s why we’re taking a look at this through the lens of a real-world patient case from Dr. Michael Shafique’s experience as an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Guest: Michael R. Shafique, MD Tune in as Dr. Michael Shafique from the Moffitt Cancer Center explains the KEYNOTE-189 clinical trial, which investigated whether the addition of pembrolizumab to standard of care platinum-based chemotherapy would provide some survival benefit to patients with non-small cell lung cancer.

Guest: Michael R. Shafique, MD To find out more about the structure, results, and implications of the REVEL trial, we spoke with Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Michael R. Shafique, MD Testing for the biomarker PD-L1 can offer clinicians direction for their treatment approach to non-small cell lung cancer, and here to offer insights on therapeutic approaches for patients with high PD-L1 expression is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.

Host: Mario R. Nacinovich, Jr., MSc Guest: Jonathan Riess, MD, MS Here to explain how our refined understandings of driver mutations, immune properties, and tumor microenvironments have changed the way we think about combination therapies, their benefits and limitations, and what’s on the horizon is Dr. Jonathan Riess, Associate Professor of Oncology and Hematology at the UC Davis Medical Center.

Guest: Michael R. Shafique, MD After many decades of trying to improve the outcomes of patients with advanced non-small cell lung cancer, we may finally have the therapeutic approach that achieves that goal: maintenance therapy. Join Dr. Michael Shafique, an Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, as he reviews the data and keys to success behind maintenance therapy.

Guest: Michael R. Shafique, MD The therapies that have been approved for non-small cell lung cancer stimulate the immune system to attack cancer cells… But what happens when they do too good a job of that and stimulate the immune system to inflame other parts of the body as well? Dr. Michael Shafique from the Moffitt Cancer Center breaks down the most common adverse events to look for in patients with non-small cell lung cancer.

Guest: Edward S. Kim, MD When looking at the non-small cell lung cancer landscape, we’re now seeing the emergence of several genetic markers that may have therapies linked to them, and one of those markers is the RET fusion that exists. Join Dr. Edward Kim as he gets us caught up on the investigational therapies targeting RET-mutated non-small cell lung cancer that just might end up in the clinic.